Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Lion's Mane (Hericium erinaceus) | Vinpocetine | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 500-3000 mg/day of fruiting body extract (standardized to >30% polysaccharides) or 1000-3000 mg/day of mycelium extract (erinacine-enriched) | 5-20 mg 2-3 times daily (15-60 mg/day total) |
| Timing | Morning or split morning/afternoon. With or without food. Effects are cumulative — expect 2-4 weeks before noticeable cognitive benefit. | With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours). |
| Cycle Duration | Ongoing; no cycling strictly required, though some users cycle 8 weeks on, 2 weeks off | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks. |
| Evidence Level | moderate_human | moderate_human |
Contains hericenones (fruiting body) and erinacines (mycelium) that stimulate nerve growth factor (NGF) synthesis in glial cells via activation of the JNK pathway. Erinacines cross the blood-brain barrier via passive diffusion and act as potent neurotrophin-stimulating compounds, activating the TrkA receptor and downstream ERK1/2 signaling cascades to promote hippocampal neurogenesis and synaptic plasticity. Also demonstrates anti-inflammatory activity through suppression of NF-kB and upregulation of BDNF expression.
500-3000 mg/day of fruiting body extract (standardized to >30% polysaccharides) or 1000-3000 mg/day of mycelium extract (erinacine-enriched)
Morning or split morning/afternoon. With or without food. Effects are cumulative — expect 2-4 weeks before noticeable cognitive benefit.
Ongoing; no cycling strictly required, though some users cycle 8 weeks on, 2 weeks off
Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.
5-20 mg 2-3 times daily (15-60 mg/day total)
With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →